期刊文献+

c-Met与GPC1在非小细胞肺癌中的表达及预后意义 被引量:5

Expression of c-Met and glypican1 in non-small-cell lung cancer and its prognostic signifi cance
下载PDF
导出
摘要 目的探究肝细胞生长因子受体(hepatocyte growth factor receptor,c-Met)与磷脂酰肌醇蛋白聚糖1(glypican 1,GPC1)在非小细胞肺癌(non-small-cell lung cancer,NSCLC)组织中的表达及临床意义。方法收集234例NSCLC患者的肿瘤组织和癌旁组织,免疫组织化学法检测组织中c-Met和GPC1的表达,并分析与患者临床病理资料之间的关系,对全部患者进行预后随访。结果c-Met和GPC1在NSCLC组织中的阳性表达率均高于其癌旁组织(均P<0.05)。两者在NSCLC组织中的表达呈正相关(r=0.706,P<0.01)。c-Met和GPC1在NSCLC组织中的阳性表达在NSCLC患者的临床分期和淋巴结转移方面比较,差异均具有统计学意义(均P<0.05)。c-Met阳性和GPC1阳性患者的5年生存率均低于阴性患者(12.6%vs 56.3%,P<0.05;5.3%vs 28.5%,P<0.05)。c-Met阳性表达、GPC1阳性表达、NSCLC临床分期以及淋巴结转移是NSCLC患者生存时间的主要影响因素(均P<0.01)。结论NSCLC患者肿瘤组织中c-Met和GPC1高表达。c-Met和GPC1阳性表达患者预后不良。 Objective To investigate the expressions of hepatocyte growth factor receptor(c-Met)and glypican 1(GPC1)in non-small-cell lung cancer(NSCLC)and its clinical significance.Methods The expressions of c-Met and GPC1 in 234 NSCLC patients were detected by immunohistochemistry,and the relationship between the expressions of c-Met and GPC1 and clinicopathological data was analyzed.Results The positive expression rates of c-Met and GPC1 in NSCLC tissues were higher than those in adjacent tissues(both P<0.05).The expressions of c-Met and GPC1 were positively correlated in NSCLC tissues(r=0.706,P<0.01).The positive expression rates of c-Met and GPC1 in NSCLC tissues were significantly different in terms of clinical stage and lymph node metastasis(all P<0.05).The 5-year survival rates of c-Met positive and GPC1 positive patients were both lower than those of negative patients(12.6%vs 56.3%,P<0.05;5.3%vs 28.5%,P<0.05).The positive expressions of c-Met and GPC1,clinical stage of NSCLC and lymph node metastasis were the risk factors affecting the survival time of NSCLC patients(all P<0.01).Conclusions c-Met and GPC1 are highly expressed in NSCLC.NSCLC patients with positive expressions of c-Met and GPC1 have poor prognosis.
作者 倪文 王羲 王奇胜 段俊伟 Ni Wen;Wang Xi;Wang Qisheng;Duan Junwei(Emergency Department,Hanchuan People's Hospital,Hanchuan 431600,China;Oncology Department,Hanchuan People's Hospital,Hanchuan 431600,China)
出处 《实用肿瘤杂志》 CAS 2020年第6期506-510,共5页 Journal of Practical Oncology
关键词 非小细胞肺癌 肝细胞生长因子受体 磷脂酰肌醇蛋白聚糖1 预后 non-small-cell lung cancer hepatocyte growth factor receptor glypican 1 prognosis
  • 相关文献

参考文献2

二级参考文献18

  • 1胡胜,宋启斌.非小细胞肺癌的靶向性治疗[J].中国肿瘤,2006,15(7):457-461. 被引量:4
  • 2Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007 [J]. CA Cancer J Clin, 2007, 57(!):43-66.
  • 3Sharma SV,Beil DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer[J]. Nat Rev Cancer, 2007, 7(3):169-181.
  • 4Hirsch FR, Varella-Garcia M, Bunn PA, et al. Molecular predictors of outcome with gefitinib in a phase Ⅲ placebo-controlled study in advanced non-small-cell lung cancer[J]. J Clin Oncol, 2006, 24(31):5034-5042.
  • 5Blackhall F, Ranson M, Thatcher N. Where next for gefitinib in patients with lung cancer?[J]. Lancet Oncol, 2006, 7(6):499-507.
  • 6Sharma SV, Gajowniczek P, Way IP, et al. A common signaling cascade may underlie "addiction" to the Src, BCRABL, and EGF receptor oncogenes[J]. Cancer Cell, 2006, 10(5):425-435.
  • 7Hubner A, Jaeschke A, Davis RJ. Oncogene addiction: role of signal attenuation[J]. Dev Cell,2006,11(6):752-754.
  • 8Sequist LV, Bell DW, Lynch TJ, et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer[J]. J Clin Oncol, 2007, 25(5):587-595.
  • 9Minami Y, Shimamura T, Shah K, et al. The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ ERBB2 inhibitor HKI-272[J]. Oncogene, 2007, [Epub ahead of print].
  • 10Bell DW, Gore I, Okimoto RA, et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR[J]. Nat Genet, 2005, 37(12): 1315-1316.

共引文献8

同被引文献44

引证文献5

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部